Joint Planning and Development Office

The TBI Action Alliance Brings Together a Passionate Community to Expedite Accurate Diagnosis and Treatments for Those Suffering from Traumatic Brain Injury

Retrieved on: 
Wednesday, November 8, 2023
TBI, Alzheimer's disease, FDA, Research, Veterans Health Administration, Chronic traumatic encephalopathy, CTE, International, Headache, Prevalence, Head injury, Dizziness, Organization, Veteran, Doctor of Philosophy, Sleep, Athlete, Brain, Caregiver, Division, Risk, Doctor of Science, Parkinson's disease, Community, Woman, DMD, Anxiety, Patient, Traumatic brain injury, Memory, Injury, Joint Planning and Development Office, National Association, Pharmaceutical industry, Neuroscience, CVB, MD, Medicine

NEW YORK, Nov. 8, 2023 /PRNewswire/ -- The TBI Action Alliance (TBIAA) today announced the first-ever large-scale coordinated effort to accelerate the development of accurate diagnostics and treatments to improve the lives of the more than 5.3 million people living with TBI-related symptoms. Founded by Cohen Veterans Bioscience (CVB) with more than 20 organizations including partners such as American Brain Coalition, National Association of Veterans' Research and Education Foundations, National Association of State Head Injury Administrators, National TBI Registry Coalition and PINK Concussions, the Alliance has come together to provide solutions to this widespread and significantly under-addressed public health crisis.

Key Points: 
  • On November 9, The TBI Action Alliance will hold its inaugural meeting in Washington DC to share and discuss its plan to address the TBI public health crisis.
  • Contributors such as Rachel Ramoni, DMD, ScD, Chief Research & Development Officer, Veterans Health Administration will provide a historical perspective and what is needed on the path ahead.
  • "Traumatic Brain Injury due to head trauma affects everyone and often devastates the lives of those affected.
  • The high prevalence of TBI creates significant impact on patients, caregivers, the health care system, and society as a whole.

EQS-News: MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting

Retrieved on: 
Tuesday, November 7, 2023
Standard of care, Primary myelofibrosis, Progression-free survival, 65th United States Congress, Ruxolitinib, Research, JAK, Society, Abstract (summary), ASH, Clinical trial, Abstract, FSE, Tafasitamab, BET, Exposition, Patient, TSS, Joint Planning and Development Office, Pharmaceutical industry, Book, MorphoSys

The conference is being held in San Diego, California, from December 9 to 12, 2023.

Key Points: 
  • The conference is being held in San Diego, California, from December 9 to 12, 2023.
  • “We will be sharing topline results from our pivotal MANIFEST-2 study in the coming weeks and look forward to presenting detailed findings at ASH 2023 shortly thereafter.
  • A total of 431 patients were randomized in the study, making it one of the largest myelofibrosis studies conducted to date.
  • One additional abstract on pelabresib and six abstracts on tafasitamab, marketed in the U.S. as Monjuvi® and outside the U.S. by Incyte as Minjuvi®, were accepted for presentation and publication at ASH 2023.

Pfizer Highlights Scientific Advances from Growing Hematology Portfolio at American Society of Hematology Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Bispecific monoclonal antibody, Science, FDA, NYSE, Food, Multiple myeloma, Haemophilia, Bone marrow, SCD, Hematology, B-cell maturation antigen, Safety, Phase 3, Sickle cell disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, Society, ASH, RRMM, Caregiver, Inc., Health equity, Abstract, PFE, Patient, BCMA, Joint Planning and Development Office, Pharmaceutical industry, Pfizer

Pfizer Inc. (NYSE: PFE) will present its latest data showcasing advances in the treatment of hemophilia, sickle cell disease, and blood cancers at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego from December 9-12.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) will present its latest data showcasing advances in the treatment of hemophilia, sickle cell disease, and blood cancers at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego from December 9-12.
  • “Pfizer has been advancing science in hematology for more than 30 years, starting with the introduction of recombinant factor replacement therapy, which became the standard of care for people living with hemophilia.
  • Fourteen abstracts focused on the treatment of SCD, including Phase 2a safety, efficacy, and pharmacodynamic data from the ongoing Phase 2/3 clinical trial study of GBT601.
  • Nineteen abstracts from our blood cancer portfolio, including six which continue to support the use of ELREXFIO, a B-cell maturation antigen (BCMA)-CD3-directed bispecific antibody immunotherapy, in patients with RRMM.

MINT HOUSE ANNOUNCES NEWEST LOCATION IN DENVER - DOWNTOWN UNION STATION

Retrieved on: 
Monday, October 30, 2023
Cholon, Heart, Coors Field, LoDo, Denver, Digital, City, Partnership, Walking, House, Millennium Bridge, Union Station, Joint Planning and Development Office, Hotel, Shorenstein

NEW YORK, Oct. 30, 2023 /PRNewswire/ -- Mint House, the premier tech-enabled flexible living option that offers spacious, premium apartment-style accommodations across the U.S., announced today the reopening of Mint House Denver – Downtown Union Station, located at 1777 Chestnut Pl, walking distance from Union Station. Mint House will operate apartment-style hospitality units in the highrise building, which just completed a substantial property-wide refurbishment. Mint House Denver – Downtown Union Station's new footprint at 1777 Chestnut Pl has doubled in capacity from its previous iteration; from studio to two-bedroom options, Mint House units offer up to three times the space of traditional short-term rentals in the heart of Denver's LoDo neighborhood.

Key Points: 
  • NEW YORK, Oct. 30, 2023 /PRNewswire/ -- Mint House , the premier tech-enabled flexible living option that offers spacious, premium apartment-style accommodations across the U.S., announced today the reopening of Mint House Denver – Downtown Union Station, located at 1777 Chestnut Pl, walking distance from Union Station.
  • Mint House Denver – Downtown Union Station's new footprint at 1777 Chestnut Pl has doubled in capacity from its previous iteration; from studio to two-bedroom options, Mint House units offer up to three times the space of traditional short-term rentals in the heart of Denver's LoDo neighborhood.
  • Mint House Denver – Downtown Union Station provides a premium offering that gives guests the option of nightly, short-term, or long-term living.
  • Mint House Denver Downtown - Union Station is a great representation of Mint House's premium residential hospitality model."

Kobra East & Gekko (KEG) on stream ahead of plan

Retrieved on: 
Thursday, October 26, 2023
FPSO, IL Tyrving, OTCQX, KEG, Joint Planning and Development Office, Ministry of Petroleum and Energy, Ministry, PDO, Partnership, Peter Dolving, CO2, Investment, ConocoPhillips, Petroleum, Natural gas, Construction, Beer, Alvheim FPSO

FORNEBU, Norway, Oct. 26, 2023 /PRNewswire/ -- Aker BP (OSE: AKRBP) (OTCQX: AKRBF) (OTCQX: AKRBY) is pleased to announce that production has started from Kobra East & Gekko (KEG) in the Alvheim area.

Key Points: 
  • FORNEBU, Norway, Oct. 26, 2023 /PRNewswire/ -- Aker BP (OSE: AKRBP) (OTCQX: AKRBF) (OTCQX: AKRBY) is pleased to announce that production has started from Kobra East & Gekko (KEG) in the Alvheim area.
  • This has contributed significantly to the safely and successful 'below budget and ahead of schedule' deliveries.
  • The KEG development comprises the two discoveries Kobra East and Gekko in licence 203.
  • With KEG in production, CO2 emissions per barrel will be significantly reduced and oil production from the Alvheim FPSO substantially increased.

U.S. FDA Approves Pfizer’s BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer

Retrieved on: 
Thursday, October 12, 2023
Biotechnology, FDA, Health, Pharmaceutical, Oncology, Annual general meeting, Constipation, JCO, Fatal, Arrhythmia, Joint Planning and Development Office, NYSE, Lung cancer, Food, Cetuximab, Myocardial infarction, Memorial Sloan Kettering Cancer Center, IRC, Plasma, Vomiting, NSCLC, Bleeding, Cough, Anemia, BRAF, Pfizer, ORR, Inc., Society, American Society of Clinical Oncology, Mutation, CRC, Disease, Diarrhea, Abdominal pain, Visual impairment, DSM-IV codes, Nausea, Rash, Periodic breathing, Journal, Fatigue, DOR, Pneumonia, Intracranial hemorrhage, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, American Journal of Clinical Oncology, MSK, ASCO, Pleural effusion, Edema, Patient, PFE, Risk, Pharmaceutical industry

“Today’s approval builds on our long-standing commitment to deliver innovative, personalized medicines to patients with lung cancer.

Key Points: 
  • “Today’s approval builds on our long-standing commitment to deliver innovative, personalized medicines to patients with lung cancer.
  • “The PHAROS trial demonstrated that these patients could benefit from BRAFTOVI + MEKTOVI targeted therapy regardless of their prior treatment history.
  • BRAFTOVI + MEKTOVI is also FDA-approved for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
  • BRAFTOVI is FDA-approved, in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.

INNOVATIONwhite™ Ceramic Knives by KYOCERA Enhance Grip Ability and Cutting Control, Available Now on Indiegogo

Retrieved on: 
Tuesday, September 19, 2023
Men, Retail, Manufacturing, Consumer, Home Goods, Online Retail, Luxury, Catalog, Other Retail, Other Consumer, Specialty, Women, Other Manufacturing, Food, Beverage, Resilience, Ceramic, Freedom, Joint Planning and Development Office, Multimedia, Research, Vegetable, Development, Protein, Corrosion, Cooking, Risk, Kyocera, Indiegogo, Kuwano

Kyocera, a global leader in advanced ceramics, announced today that the company launched its new line of ceramic knives, INNOVATIONwhite™, exclusively on Indiegogo.

Key Points: 
  • Kyocera, a global leader in advanced ceramics, announced today that the company launched its new line of ceramic knives, INNOVATIONwhite™, exclusively on Indiegogo.
  • View the full release here: https://www.businesswire.com/news/home/20230919689354/en/
    Kyocera INNOVATIONwhite ceramic knives are available in a variety of colors and knife sets, exclusively with Indiegogo for a limited time.
  • The white knives are available with white, black, red, blue, or green handles, shipping in sustainable, plastic-free retail packaging.
  • Kyocera’s traditional ultra-sharp zirconia ceramic blade will maintain its sharpness up to 10x longer than metal knives, and its INNOVATION lines double that long-lasting sharpness.

EQS-News: MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer

Retrieved on: 
Saturday, September 16, 2023
Ruxolitinib, Peripheral T-cell lymphoma, MorphoSys, Half-life, Tafasitamab, Joint Planning and Development Office, Fast Track, FSE, Immunotherapy, B-cell lymphoma, ASCO, BET, Squamous-cell carcinoma, Endometrial cancer, American Society of Clinical Oncology, Patient, ARID1A, Lymphoma, Annual general meeting, FDA, EZH1, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Food, EZH2, Pharmaceutical industry

The FDA grants Fast Track designation to facilitate the development and expedite the review of medicines intended to treat serious conditions and potentially address an unmet medical need, with the goal of getting these important, new therapies to patients earlier.

Key Points: 
  • The FDA grants Fast Track designation to facilitate the development and expedite the review of medicines intended to treat serious conditions and potentially address an unmet medical need, with the goal of getting these important, new therapies to patients earlier.
  • The Fast Track designation in endometrial cancer was granted based on preclinical results and preliminary clinical data from an ongoing Phase 1/2 study.
  • “Receiving Fast Track designation from the FDA for tulmimetostat in ARID1A-mutated endometrial cancer underscores this investigational therapy’s potential in a patient population with limited treatment options,” said Tim Demuth, M.D., Ph.D., MorphoSys Chief Research and Development Officer.
  • Pelabresib, an investigational BET inhibitor, received Fast Track designation for myelofibrosis in 2018, and tafasitamab, a CD19-targeting immunotherapy, received this designation for relapsed or refractory diffuse large B-cell lymphoma in 2014.

Tom Donahue Joins DIV Industrial as Partner and Head of Development

Retrieved on: 
Thursday, September 7, 2023
Commercial Building & Real Estate, Construction & Property, Professional Services, Environmental, Social and Governance (ESG), Transport, DEI (Diversity, Equity and Inclusion), Logistics, Supply Chain Management, Environment, Other Construction & Property, Finance, Sustainability, Dorado, Entrepreneurship, Donahue, ESG, DIV, Joint Planning and Development Office, Prologis, Partner (business rank), Multimedia, Safety, Partner, Mootness, LEED, Construction, Inland Empire

DIV Industrial , an institutional-level investor and developer of industrial real estate, today announced the appointment of Tom Donahue as Partner and Head of Development.

Key Points: 
  • DIV Industrial , an institutional-level investor and developer of industrial real estate, today announced the appointment of Tom Donahue as Partner and Head of Development.
  • His expertise and proven track record bolsters DIV Industrial's capabilities and position as a leader in sustainable development within the industrial sector.
  • View the full release here: https://www.businesswire.com/news/home/20230907436326/en/
    Tom Donahue, Partner and Head of Development, DIV Industrial (Photo: Business Wire)
    “Tom adds immense value to DIV Industrial, and we are excited to officially have him aboard,” said Nicholas Ilagan, Co-Founder and Managing Partner at DIV Industrial.
  • “DIV Industrial is a terrific organization making a significant positive impact in commercial real estate and the industrial sector,” said Donahue.

KYOCERA Launches INNOVATIONwhite™ Ceramic Kitchen Knives, a Collaboration with Award-Winning Designer Yohei Kuwano

Retrieved on: 
Tuesday, August 8, 2023
Resilience, Ceramic, Freedom, Joint Planning and Development Office, Research, Vegetable, Development, Protein, Corrosion, Cooking, Risk, SAN, Abrasive, Kyocera, Indiegogo, Kuwano

SAN DIEGO, Aug. 8, 2023 /PRNewswire-PRWeb/ -- Kyocera, a global leader in advanced ceramics, has launched INNOVATIONwhite™, a new line of ceramic kitchen knives designed by Japan's award-winning Yohei Kuwano. The new line features five vibrant colors and is available exclusively on Indiegogo for a limited time.

Key Points: 
  • SAN DIEGO, Aug. 8, 2023 /PRNewswire-PRWeb/ -- Kyocera, a global leader in advanced ceramics, has launched INNOVATIONwhite™, a new line of ceramic kitchen knives designed by Japan's award-winning Yohei Kuwano.
  • The white knives are available with white, black, red, blue, or green handles, shipping in sustainable, plastic-free retail packaging.
  • The design collaboration with Tokyo-based designer Yohei Kuwano , a first for Kyocera, reflects the company's commitment to innovation and design excellence.
  • An accomplished product designer, Kuwano has received 16 design awards in the last two decades.